Abstract
To provide a reference for finding a reasonable evaluation method for treatment effect of radiofrequency ablation (RFA), computed tomography (CT) image optimized by the intelligent segmentation algorithm was utilized to evaluate the liver condition of hepatocellular carcinoma (HCC) patients after RFA and to estimate the patient’s prognosis. Eighty-eight patients with HCC who needed RFA surgery after diagnosis in our hospital were selected. The CT images before optimization were set as the control group; the CT images after optimization were set as the observation group. Comprehensive diagnosis was taken as the gold standard to compare the ablation range and residual lesions under CT scans before and after surgery. The results showed that the consistency of the two sets of CT images was compared with comprehensive diagnosis under different diameters of the lesion. The difference between the two groups was not statistically considerable when the diameter of the lesion was less than 50 mm ( P > 0.05 ). For lesions larger than 50 mm in diameter, the consistency of the observation group (83%) was remarkably higher than that of the control group (40%), and the difference was substantial ( P < 0.05 ). The kappa value of the observation group was 0.84 and that of the control group was 0.78. The kappa value of observation group was better than the control group, with considerable difference ( P < 0.05 ). In conclusion, the diagnostic effect of CT image based on intelligent segmentation algorithm was superior to conventional diagnosis when the diameter of the lesion was larger than 50 mm. Moreover, the overall improvement rate of patients after RFA treatment was far greater than the recurrence rate, indicating that the clinical adoption of RFA was very meaningful.
Highlights
Liver cancer refers to malignant tumors that occur in liver tissue, which is mainly classified into two categories: primary hepatic carcinoma and secondary liver cancer
Intelligent segmentation algorithm was used to separate and optimize the liver lesions and normal tissues of all patients. e computed tomography (CT) images of all patients were classified into two groups according to whether they were optimized or not. e CT images before optimization were set as the control group, and the optimized CT images were set as the observation group. e comprehensive diagnosis of laboratory examination, imaging examination, and pathological results was taken as the “gold standard.” e results of the two groups of imaging examination were analyzed and compared to evaluate their adoption value. e study was approved by the Medical Ethics Committee
Inclusion criteria: (1) all patients met hepatocellular carcinoma (HCC)-related diagnostic criteria [18] and were confirmed by pathological results; (2) all patients had single-focus primary HCC; (3) all the patients were between 18 and 78 years old; (4) none of the patients had received other preoperative antitumor therapy; (5) patients and their family members knew about this study and signed the consent form; (6) liver function was classified according to the Child-Pugh grading standard [19] (Figure 1), and the Child-Pugh grading of liver function was all grade A or B; (7) contrast-enhanced CT (CECT) examination was completed in all patients after Radiofrequency ablation (RFA)
Summary
Liver cancer refers to malignant tumors that occur in liver tissue, which is mainly classified into two categories: primary hepatic carcinoma and secondary liver cancer. E incidence of hepatocellular carcinoma (HCC) in primary liver cancer is relatively high [1,2,3]. HCC occupies a high ranking in the incidence of various malignant tumors. E main treatment for HCC is surgical resection [6]. Surgical treatment can effectively remove tumor lesions and improve the prognosis of the diseases, but not all patients are suitable to do so. Some HCC patients may have symptoms such as liver cirrhosis during the progression of the disease, leading to insufficient liver function and unable to compensate for the effects of surgical resection, which makes HCC treatment require further development and improvement [7]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
